Liver protein profiling in chronic hepatitis C: Identification of potential predictive markers for interferon therapy outcome

Journal of Proteome Research

Volumn 11, Issue 2, 2012, Pages 717-727

  Perdomo, Ariel Basulto ^a   Ciccosanti, Fabiola ^a   Iacono, Oreste Lo ^b   Angeletti, Claudio ^a   Corazzari, Marco ^a   Daniele, Nicola ^a   Testa, Angela ^a   Pisa, Roberto ^c   Ippolito, Giuseppe ^a   Antonucci, Giorgio ^a   Fimia, Gian Maria ^a   Piacentini, Mauro ^a,d  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Aranjuez   (Spain)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

2 D DIGE; antiviral therapy; HCV; liver biopsy; prognostic markers

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; ACONITATE HYDRATASE; CATALASE; CYTOCHROME P450 REDUCTASE; DIHYDRODIOL DEHYDROGENASE; ELONGATION FACTOR TU; FRUCTOSE BISPHOSPHATE ALDOLASE; GLYCINE AMIDINOTRANSFERASE; INTERFERON; LIVER PROTEIN; ORNITHINE OXOACID AMINOTRANSFERASE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; STAT1 PROTEIN; SUCCINATE DEHYDROGENASE; VIMENTIN;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIVER BIOPSY; MASS SPECTROMETRY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; RETROSPECTIVE STUDY; STRESS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOPSY; CLUSTER ANALYSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; POLYETHYLENE GLYCOLS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEOME; PROTEOMICS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84856668107     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr2006445     Document Type: Article

References (49)

1. Seeff, L. B.; Hoofnagle, J. H. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002 Clin. Liver Dis. 2003, 7, 261-287
2. Lavanchy, D. The global burden of hepatitis C Liver Int. 2009, 29 (Suppl 1) 74-81
3. Lauer, G. M.; Walker, B. D. Hepatitis C virus infection N. Engl. J. Med. 2001, 345, 41-52
4. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.; Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001, 358, 958-965
5. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Goncales, F. L., Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 2002, 347, 975-982
6. Hadziyannis, S. J.; Sette, H., Jr.; Morgan, T. R.; Balan, V.; Diago, M.; Marcellin, P.; Ramadori, G.; Bodenheimer, H., Jr.; Bernstein, D.; Rizzetto, M.; Zeuzem, S.; Pockros, P. J.; Lin, A.; Ackrill, A. M. PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann. Intern. Med. 2004, 140, 346-355
7. Mihm, U.; Herrmann, E.; Sarrazin, C.; Zeuzem, S. Review article: predicting response in hepatitis C virus therapy Aliment. Pharmacol. Ther. 2006, 23, 1043-1054
8. Ghany, M. G.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update Hepatology 2009, 49, 1335-1374
9. Ge, D.; Fellay, J.; Thompson, A. J.; Simon, J. S.; Shianna, K. V.; Urban, T. J.; Heinzen, E. L.; Qiu, P.; Bertelsen, A. H.; Muir, A. J.; Sulkowski, M.; McHutchison, J. G.; Goldstein, D. B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 2009, 461, 399-401
10. Suppiah, V.; Moldovan, M.; Ahlenstiel, G.; Berg, T.; Weltman, M.; Abate, M. L.; Bassendine, M.; Spengler, U.; Dore, G. J.; Powell, E.; Riordan, S.; Sheridan, D.; Smedile, A.; Fragomeli, V.; Muller, T.; Bahlo, M.; Stewart, G. J.; Booth, D. R.; George, J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 2009, 41, 1100-1104
11. Tanaka, Y.; Nishida, N.; Sugiyama, M.; Kurosaki, M.; Matsuura, K.; Sakamoto, N.; Nakagawa, M.; Korenaga, M.; Hino, K.; Hige, S.; Ito, Y.; Mita, E.; Tanaka, E.; Mochida, S.; Murawaki, Y.; Honda, M.; Sakai, A.; Hiasa, Y.; Nishiguchi, S.; Koike, A.; Sakaida, I.; Imamura, M.; Ito, K.; Yano, K.; Masaki, N.; Sugauchi, F.; Izumi, N.; Tokunaga, K.; Mizokami, M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat. Genet. 2009, 41, 1105-1109
12. Thomas, D. L.; Thio, C. L.; Martin, M. P.; Qi, Y.; Ge, D.; O'Huigin, C.; Kidd, J.; Kidd, K.; Khakoo, S. I.; Alexander, G.; Goedert, J. J.; Kirk, G. D.; Donfield, S. M.; Rosen, H. R.; Tobler, L. H.; Busch, M. P.; McHutchison, J. G.; Goldstein, D. B.; Carrington, M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 2009, 461, 798-801
13. Chen, L.; Borozan, I.; Feld, J.; Sun, J.; Tannis, L. L.; Coltescu, C.; Heathcote, J.; Edwards, A. M.; McGilvray, I. D. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 2005, 128, 1437-1444
14. Feld, J. J.; Nanda, S.; Huang, Y.; Chen, W.; Cam, M.; Pusek, S. N.; Schweigler, L. M.; Theodore, D.; Zacks, S. L.; Liang, T. J.; Fried, M. W. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response Hepatology 2007, 46, 1548-1563
15. Sarasin-Filipowicz, M.; Oakeley, E. J.; Duong, F. H.; Christen, V.; Terracciano, L.; Filipowicz, W.; Heim, M. H. Interferon signaling and treatment outcome in chronic hepatitis C Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 7034-7039
16. Asselah, T.; Bieche, I.; Narguet, S.; Sabbagh, A.; Laurendeau, I.; Ripault, M. P.; Boyer, N.; Martinot-Peignoux, M.; Valla, D.; Vidaud, M.; Marcellin, P. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C Gut 2008, 57, 516-524
17. Ishak, K.; Baptista, A.; Bianchi, L.; Callea, F.; De Groote, J.; Gudat, F.; Denk, H.; Desmet, V.; Korb, G.; MacSween, R. N. Histological grading and staging of chronic hepatitis J. Hepatol. 1995, 22, 696-699
18. Scheuer, P. J. Classification of chronic viral hepatitis: a need for reassessment J. Hepatol. 1991, 13, 372-374
19. Ciccosanti, F.; Corazzari, M.; Soldani, F.; Matarrese, P.; Pagliarini, V.; Iadevaia, V.; Tinari, A.; Zaccarelli, M.; Perfettini, J. L.; Malorni, W.; Kroemer, G.; Antinori, A.; Fimia, G. M.; Piacentini, M. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients Antiviral Ther. 2010, 15, 377-390
20. Unlu, M.; Morgan, M. E.; Minden, J. S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts Electrophoresis 1997, 18, 2071-2077
21. Van den Bergh, G.; Arckens, L. Recent advances in 2D electrophoresis: an array of possibilities Expert Rev. Proteomics 2005, 2, 243-252
22. Patel, K.; Lucas, J. E.; Thompson, J. W.; Dubois, L. G.; Tillmann, H. L.; Thompson, A. J.; Uzarski, D.; Califf, R. M.; Moseley, M. A.; Ginsburg, G. S.; McHutchison, J. G.; McCarthy, J. J. MURDOCK Horizon 1 Study Team High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients Hepatology 2011, 53, 1809-1818
23. Younossi, Z. M.; Limongi, D.; Stepanova, M.; Pierobon, M.; Afendy, A.; Mehta, R.; Baranova, A.; Liotta, L.; Petricoin, E. Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) J. Proteome Res. 2011, 10, 774-779
24. Devitt, E. J.; Power, K. A.; Lawless, M. W.; Browne, J. A.; Gaora, P. O.; Gallagher, W. M.; Crowe, J. Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon alpha-2b and ribavirin Eur. J. Gastroenterol. Hepatol. 2011, 23, 177-183
25. Fujita, N.; Nakanishi, M.; Mukai, J.; Naito, Y.; Ichida, T.; Kaito, M.; Yoshikawa, T.; Takei, Y. Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis Mol. Med. 2011, 17, 70-78
26. Molina, S.; Misse, D.; Roche, S.; Badiou, S.; Cristol, J. P.; Bonfils, C.; Dierick, J. F.; Veas, F.; Levayer, T.; Bonnefont-Rousselot, D.; Maurel, P.; Coste, J.; Fournier-Wirth, C. Identification of apolipoprotein C-III as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection Proteomics Clin. Appl. 2008, 2, 751-761
27. Asselah, T.; Bieche, I.; Paradis, V.; Bedossa, P.; Vidaud, M.; Marcellin, P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C Semin. Liver Dis. 2007, 27, 13-27
28. Paradis, V.; Asselah, T.; Dargere, D.; Ripault, M. P.; Martinot, M.; Boyer, N.; Valla, D.; Marcellin, P.; Bedossa, P. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin Gastroenterology 2006, 130, 2189-2197
29. Najjar, I.; Fagard, R. STAT1 and pathogens, not a friendly relationship Biochimie 2010, 92, 425-444
30. Haller, O.; Staeheli, P.; Kochs, G. Interferon-induced Mx proteins in antiviral host defense Biochimie 2007, 89, 812-818
31. MacQuillan, G. C.; de Boer, W. B.; Platten, M. A.; McCaul, K. A.; Reed, W. D.; Jeffrey, G. P.; Allan, J. E. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection J. Med. Virol. 2002, 68, 197-205
32. Giannelli, G.; Guadagnino, G.; Dentico, P.; Antonelli, G.; Antonaci, S. MxA and PKR expression in chronic hepatitis C J. Interferon Cytokine Res. 2004, 24, 659-663
33. Melen, K.; Fagerlund, R.; Nyqvist, M.; Keskinen, P.; Julkunen, I. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs J. Med. Virol. 2004, 73, 536-547
34. Yan, W.; Lee, H.; Yi, E. C.; Reiss, D.; Shannon, P.; Kwieciszewski, B. K.; Coito, C.; Li, X. J.; Keller, A.; Eng, J.; Galitski, T.; Goodlett, D. R.; Aebersold, R.; Katze, M. G. System-based proteomic analysis of the interferon response in human liver cells Genome Biol. 2004, 5, R54
35. Feld, J. J.; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 2005, 436, 967-972
36. Lan, K. H.; Lan, K. L.; Lee, W. P.; Sheu, M. L.; Chen, M. Y.; Lee, Y. L.; Yen, S. H.; Chang, F. Y.; Lee, S. D. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines J. Hepatol. 2007, 46, 759-767
37. Urban, T. J.; Thompson, A. J.; Bradrick, S. S.; Fellay, J.; Schuppan, D.; Cronin, K. D.; Hong, L.; McKenzie, A.; Patel, K.; Shianna, K. V.; McHutchison, J. G.; Goldstein, D. B.; Afdhal, N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 2010, 52, 1888-1896
38. Diao, F.; Li, S.; Tian, Y.; Zhang, M.; Xu, L. G.; Zhang, Y.; Wang, R. P.; Chen, D.; Zhai, Z.; Zhong, B.; Tien, P.; Shu, H. B. Negative regulation of MDA5- but not RIG-I-mediated innate antiviral signaling by the dihydroxyacetone kinase Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 11706-11711
39. Bachler, C.; Flukiger-Bruhwiler, K.; Schneider, P.; Bahler, P.; Erni, B. From ATP as substrate to ADP as coenzyme: functional evolution of the nucleotide binding subunit of dihydroxyacetone kinases J. Biol. Chem. 2005, 280, 18321-18325
40. Barski, O. A.; Tipparaju, S. M.; Bhatnagar, A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification Drug Metab. Rev. 2008, 40, 553-624
41. Hara, A.; Matsuura, K.; Tamada, Y.; Sato, K.; Miyabe, Y.; Deyashiki, Y.; Ishida, N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells Biochem. J. 1996, 313 (Pt 2) 373-376
42. Iwata, R.; Stieger, B.; Mertens, J. C.; Muller, T.; Baur, K.; Frei, P.; Braun, J.; Vergopoulos, A.; Martin, I. V.; Schmitt, J.; Goetze, O.; Bibert, S.; Bochud, P. Y.; Mullhaupt, B.; Berg, T.; Geier, A.; Swiss Hepatitis C Cohort Study Group The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C. J. Viral Hepat. 2010.
43. Jinno, K.; Tanimizu, M.; Hyodo, I.; Nishikawa, Y.; Hosokawa, Y.; Doi, T.; Endo, H.; Yamashita, T.; Okada, Y. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma J. Gastroenterol. 1998, 33, 376-382
44. Morinaga, S.; Yamamoto, Y.; Noguchi, Y.; Imada, T.; Rino, Y.; Akaike, M.; Sugimasa, Y.; Takemiya, S.; Takanashi, Y. Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver Hepatogastroenterology 2003, 50, 1521-1526
45. Poon, R. T.; Lau, C. P.; Cheung, S. T.; Yu, W. C.; Fan, S. T. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma Cancer Res. 2003, 63, 3121-3126
46. Mas, V. R.; Maluf, D. G.; Archer, K. J.; Yanek, K. C.; Fisher, R. A. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation Transplantation 2007, 84, 1262-1271
47. Salcedo, X.; Medina, J.; Sanz-Cameno, P.; Garcia-Buey, L.; Martin-Vilchez, S.; Borque, M. J.; Lopez-Cabrera, M.; Moreno-Otero, R. The potential of angiogenesis soluble markers in chronic hepatitis C Hepatology 2005, 42, 696-701
48. Galluzzi, L.; Brenner, C.; Morselli, E.; Touat, Z.; Kroemer, G. Viral control of mitochondrial apoptosis PLoS Pathog. 2008, 4, e1000018
49. Lussier, M. P.; Cayouette, S.; Lepage, P. K.; Bernier, C. L.; Francoeur, N.; St-Hilaire, M.; Pinard, M.; Boulay, G. MxA, a member of the dynamin superfamily, interacts with the ankyrin-like repeat domain of TRPC J. Biol. Chem. 2005, 280, 19393-19400